Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Hutson, Thomas E [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013 |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London |
|---|---|
| Übergeordnetes Werk: |
volume:14 ; year:2013 ; number:13 ; pages:1287-1294 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1470-2045(13)70465-0 |
|---|
| Katalog-ID: |
ELV027050181 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV027050181 | ||
| 003 | DE-627 | ||
| 005 | 20230623185217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(13)70465-0 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013004000012.pica |
| 035 | |a (DE-627)ELV027050181 | ||
| 035 | |a (ELSEVIER)S1470-2045(13)70465-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 35.70 |2 bkl | ||
| 084 | |a 42.12 |2 bkl | ||
| 100 | 1 | |a Hutson, Thomas E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial |
| 264 | 1 | |c 2013 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma. | ||
| 700 | 1 | |a Lesovoy, Vladimir |4 oth | |
| 700 | 1 | |a Al-Shukri, Salman |4 oth | |
| 700 | 1 | |a Stus, Viktor P |4 oth | |
| 700 | 1 | |a Lipatov, Oleg N |4 oth | |
| 700 | 1 | |a Bair, Angel H |4 oth | |
| 700 | 1 | |a Rosbrook, Brad |4 oth | |
| 700 | 1 | |a Chen, Connie |4 oth | |
| 700 | 1 | |a Kim, Sinil |4 oth | |
| 700 | 1 | |a Vogelzang, Nicholas J |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n The Lancet Publ. Group |a Citovsky, Vitaly ELSEVIER |t My |d 2019 |g London |w (DE-627)ELV003173852 |
| 773 | 1 | 8 | |g volume:14 |g year:2013 |g number:13 |g pages:1287-1294 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(13)70465-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
| 936 | b | k | |a 42.12 |j Biophysik |q VZ |
| 951 | |a AR | ||
| 952 | |d 14 |j 2013 |e 13 |h 1287-1294 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
t e h te teh |
|---|---|
| matchkey_str |
hutsonthomaselesovoyvladimiralshukrisalm:2013----:xtnbessoaeiafrtiehrpiptetwtmtsairnlelacnma |
| hierarchy_sort_str |
2013 |
| bklnumber |
35.70 42.12 |
| publishDate |
2013 |
| allfields |
10.1016/S1470-2045(13)70465-0 doi GBVA2013004000012.pica (DE-627)ELV027050181 (ELSEVIER)S1470-2045(13)70465-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Hutson, Thomas E verfasserin aut Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial 2013 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma. Lesovoy, Vladimir oth Al-Shukri, Salman oth Stus, Viktor P oth Lipatov, Oleg N oth Bair, Angel H oth Rosbrook, Brad oth Chen, Connie oth Kim, Sinil oth Vogelzang, Nicholas J oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:14 year:2013 number:13 pages:1287-1294 extent:8 https://doi.org/10.1016/S1470-2045(13)70465-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 14 2013 13 1287-1294 8 045F 610 |
| spelling |
10.1016/S1470-2045(13)70465-0 doi GBVA2013004000012.pica (DE-627)ELV027050181 (ELSEVIER)S1470-2045(13)70465-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Hutson, Thomas E verfasserin aut Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial 2013 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma. Lesovoy, Vladimir oth Al-Shukri, Salman oth Stus, Viktor P oth Lipatov, Oleg N oth Bair, Angel H oth Rosbrook, Brad oth Chen, Connie oth Kim, Sinil oth Vogelzang, Nicholas J oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:14 year:2013 number:13 pages:1287-1294 extent:8 https://doi.org/10.1016/S1470-2045(13)70465-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 14 2013 13 1287-1294 8 045F 610 |
| allfields_unstemmed |
10.1016/S1470-2045(13)70465-0 doi GBVA2013004000012.pica (DE-627)ELV027050181 (ELSEVIER)S1470-2045(13)70465-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Hutson, Thomas E verfasserin aut Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial 2013 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma. Lesovoy, Vladimir oth Al-Shukri, Salman oth Stus, Viktor P oth Lipatov, Oleg N oth Bair, Angel H oth Rosbrook, Brad oth Chen, Connie oth Kim, Sinil oth Vogelzang, Nicholas J oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:14 year:2013 number:13 pages:1287-1294 extent:8 https://doi.org/10.1016/S1470-2045(13)70465-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 14 2013 13 1287-1294 8 045F 610 |
| allfieldsGer |
10.1016/S1470-2045(13)70465-0 doi GBVA2013004000012.pica (DE-627)ELV027050181 (ELSEVIER)S1470-2045(13)70465-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Hutson, Thomas E verfasserin aut Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial 2013 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma. Lesovoy, Vladimir oth Al-Shukri, Salman oth Stus, Viktor P oth Lipatov, Oleg N oth Bair, Angel H oth Rosbrook, Brad oth Chen, Connie oth Kim, Sinil oth Vogelzang, Nicholas J oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:14 year:2013 number:13 pages:1287-1294 extent:8 https://doi.org/10.1016/S1470-2045(13)70465-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 14 2013 13 1287-1294 8 045F 610 |
| allfieldsSound |
10.1016/S1470-2045(13)70465-0 doi GBVA2013004000012.pica (DE-627)ELV027050181 (ELSEVIER)S1470-2045(13)70465-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Hutson, Thomas E verfasserin aut Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial 2013 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma. Lesovoy, Vladimir oth Al-Shukri, Salman oth Stus, Viktor P oth Lipatov, Oleg N oth Bair, Angel H oth Rosbrook, Brad oth Chen, Connie oth Kim, Sinil oth Vogelzang, Nicholas J oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:14 year:2013 number:13 pages:1287-1294 extent:8 https://doi.org/10.1016/S1470-2045(13)70465-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 14 2013 13 1287-1294 8 045F 610 |
| language |
English |
| source |
Enthalten in My London volume:14 year:2013 number:13 pages:1287-1294 extent:8 |
| sourceStr |
Enthalten in My London volume:14 year:2013 number:13 pages:1287-1294 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Biochemie: Allgemeines Biophysik |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
My |
| authorswithroles_txt_mv |
Hutson, Thomas E @@aut@@ Lesovoy, Vladimir @@oth@@ Al-Shukri, Salman @@oth@@ Stus, Viktor P @@oth@@ Lipatov, Oleg N @@oth@@ Bair, Angel H @@oth@@ Rosbrook, Brad @@oth@@ Chen, Connie @@oth@@ Kim, Sinil @@oth@@ Vogelzang, Nicholas J @@oth@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003173852 |
| dewey-sort |
3610 |
| id |
ELV027050181 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV027050181</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623185217.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(13)70465-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013004000012.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV027050181</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(13)70465-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hutson, Thomas E</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lesovoy, Vladimir</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Al-Shukri, Salman</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stus, Viktor P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lipatov, Oleg N</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bair, Angel H</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rosbrook, Brad</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Connie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Sinil</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vogelzang, Nicholas J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:13</subfield><subfield code="g">pages:1287-1294</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(13)70465-0</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2013</subfield><subfield code="e">13</subfield><subfield code="h">1287-1294</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Hutson, Thomas E |
| spellingShingle |
Hutson, Thomas E ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial |
| authorStr |
Hutson, Thomas E |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003173852 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial |
| topic |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_unstemmed |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_browse |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
v l vl s a s sas v p s vp vps o n l on onl a h b ah ahb b r br c c cc s k sk n j v nj njv |
| hierarchy_parent_title |
My |
| hierarchy_parent_id |
ELV003173852 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology |
| hierarchy_top_title |
My |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003173852 |
| title |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial |
| ctrlnum |
(DE-627)ELV027050181 (ELSEVIER)S1470-2045(13)70465-0 |
| title_full |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial |
| author_sort |
Hutson, Thomas E |
| journal |
My |
| journalStr |
My |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
1287 |
| author_browse |
Hutson, Thomas E |
| container_volume |
14 |
| physical |
8 |
| class |
610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Hutson, Thomas E |
| doi_str_mv |
10.1016/S1470-2045(13)70465-0 |
| dewey-full |
610 570 |
| title_sort |
axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial |
| title_auth |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial |
| abstract |
In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma. |
| abstractGer |
In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma. |
| abstract_unstemmed |
In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| container_issue |
13 |
| title_short |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial |
| url |
https://doi.org/10.1016/S1470-2045(13)70465-0 |
| remote_bool |
true |
| author2 |
Lesovoy, Vladimir Al-Shukri, Salman Stus, Viktor P Lipatov, Oleg N Bair, Angel H Rosbrook, Brad Chen, Connie Kim, Sinil Vogelzang, Nicholas J |
| author2Str |
Lesovoy, Vladimir Al-Shukri, Salman Stus, Viktor P Lipatov, Oleg N Bair, Angel H Rosbrook, Brad Chen, Connie Kim, Sinil Vogelzang, Nicholas J |
| ppnlink |
ELV003173852 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1470-2045(13)70465-0 |
| up_date |
2024-07-06T20:57:34.740Z |
| _version_ |
1803864721054498816 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV027050181</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623185217.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(13)70465-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013004000012.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV027050181</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(13)70465-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hutson, Thomas E</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free survival than those treated with sorafenib. We therefore undertook a phase 3 trial comparing axitinib with sorafenib in patients with treatment-naive metastatic renal-cell carcinoma.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lesovoy, Vladimir</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Al-Shukri, Salman</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stus, Viktor P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lipatov, Oleg N</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bair, Angel H</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rosbrook, Brad</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Connie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Sinil</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vogelzang, Nicholas J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:13</subfield><subfield code="g">pages:1287-1294</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(13)70465-0</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2013</subfield><subfield code="e">13</subfield><subfield code="h">1287-1294</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4000416 |